Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism

Journal of Vascular Surgery

Volumn 49, Issue 5, 2009, Pages 1296-1303

  Bakken, Andrew M ^a   Protack, Clinton D ^a   Roztocil, Elisa ^a   Nicholl, Suzanne M ^a   Davies, Mark G ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADAM 10 PROTEIN; ADAM 12 PROTEIN; ADAM 9 PROTEIN; ADAM PROTEIN; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; ILOMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CORONARY ARTERY; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL MOVEMENT; CELLS, CULTURED; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS; TYRPHOSTINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 65249111522     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.12.026     Document Type: Article

References (35)

1. Davies M.G., and Hagen P.O. Pathobiology of intimal hyperplasia. Br J Surg 81 (1994) 1254-1269
2. Strauss B.H., Lau H.K., Bowman K.A., Sparkes J., Chisholm R.J., Garvey M.B., et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 100 (1999) 1616-1622
3. Nicholl S.M., Roztocil E., and Davies M.G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 4 (2006) 101-116
4. Blasi F., and Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Moll Cell Biol 3 (2002) 932-943
5. Preissner K.T., Kanse S.M., and May A.E. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 12 (2000) 621-628
6. Nicholl S.M., Roztocil E., and Davies M.G. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. J Vasc Surg 41 (2005) 672-681
7. Stepanova V., Mukhina S., Köhler E., Resink T.J., Erne P., and Tkachuk V.A. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms. Mol Cell Biochem 195 (1999) 199-206
8. Nguyen D.H., Hussaini I.M., and Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273 (1998) 8502-8507
9. Resnati M., Pallavicini I., Wang J.M., Oppenheim J., Serhan C.N., Romano M., and Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 99 (2002) 1359-1364
10. Tanski W.J., Fegley A.J., Roztocil E., and Davies M.G. Domain-dependent action of urokinase on smooth muscle cell responses. J Vasc Surg 39 (2004) 214-222
11. Galaria I.I., Nicholl S.M., Roztocil E., and Davies M.G. Urokinase-induced smooth muscle cell migration requires PI3-K and activation. J Surg Res 127 (2005) 46-52
12. Wetzker R., and Böhmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4 (2003) 651-657
13. Pierce K.L., Tohgo A., Ahn S., Field M.E., Luttrell L.M., and Lefkowitz R.J. Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J Biol Chem 276 (2001) 23155-23160
14. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., and Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 (1999) 884-888
15. Tanski W.J., Nicholl S.M., Kim D., Fegley A.J., Roztocil E., and Davies M.G. Sphingosine-1-phosphate-induced smooth muscle cell migration involves the mammalian target of rapamycin. J Vasc Surg 41 (2005) 91-98
16. Kalmes A., Vesti B.R., Daum G., Abraham J.A., and Clowes A.W. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 87 (2000) 92-98
17. Barnes C.J., and Kumar R. Biology of the epidermal growth factor receptor family. Cancer Treat Res 119 (2004) 1-13
18. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 15 (2003) 143-148
19. Pastore C.J., Isner J.M., Bacha P.A., Kearney M., and Pickering J.G. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Results of local versus systemic administration. Circ Res 77 (1995) 519-529
20. Trieu V.N., Narla R.K., Myers D.E., and Uckun F.M. EGF-genistein inhibits neointimal hyperplasia after vascular injury in an experimental restenosis model. J Cardiovasc Pharmacol 35 (2000) 595-605
21. Chan A.K., Kalmes A., Hawkins S., Daum G., and Clowes A.W. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg 37 (2003) 644-649
22. Carmeliet P., Moons L., Herbert J.M., Crawley J., Lupu F., Lijnen R., and Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 81 (1997) 829-839
23. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaître V., Tipping P., et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17 (1997) 439-444
24. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., and Gerard R.D. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96 (1997) 3180-3191
25. Carmeliet P., Moons L., Ploplis V., Plow E., and Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 99 (1997) 200-208
26. Nakata A., Miyagawa J., Yamashita S., Nishida M., Tamura R., Yamamori K., et al. Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis. Circulation 94 (1996) 2778-2786
27. Reape T.J., Wilson V.J., Kanczler J.M., Ward J.P., Burnand K.G., and Thomas C.R. Detection and cellular localization of heparin-binding epidermal growth factor-like growth factor mRNA and protein in human atherosclerotic tissue. J Mol Cell Cardiol 29 (1997) 1639-1648
28. Igura T., Kawata S., Miyagawa J., Inui Y., Tamura S., Fukuda K., et al. Expression of heparin-binding epidermal growth factor-like growth factor in neointimal cells induced by balloon injury in rat carotid arteries. Arterioscler Thromb Vasc Biol 16 (1996) 1524-1531
29. Raab G., and Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333 (1997) F179-F199
30. Miyagawa J., Higashiyama S., Kawata S., Inui Y., Tamura S., Yamamoto K., et al. Localization of heparin EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaque. J Clin Invest 95 (1995) 404-411
31. Berk B.C. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 81 (2001) 999-1030
32. Besner G.E., Whelton D., Crissman-Combs M.A., Steffen C.L., Kim G.Y., and Brigstock D.R. Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments. Growth Factors 7 (1992) 289-296
33. Suzuki M., Raab G., Moses M.A., Fernandez C.A., and Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272 (1997) 31730-31737
34. Nanba D., and Higashiyama S. Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev 15 (2004) 13-19
35. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8 (2002) 35-40